Trial Profile
Phase I study of low-dose hypomethylating agent azacitidine combined with histone deacetylase inhibitor valproic acid in patients with advanced cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Valproic acid (Primary)
- Indications Cancer
- Focus Adverse reactions
- 03 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 26 Jun 2009 Actual end date (1 Oct 2009) added as reported by ClinicalTrials.gov.